- Report
- July 2024
- 88 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- January 2024
- 108 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- May 2022
- 36 Pages
Global
From €1820EUR$2,000USD£1,560GBP
- Report
- July 2022
- 315 Pages
Global
From €3249EUR$3,570USD£2,785GBP
Hemoglobinopathies are a group of inherited blood disorders caused by abnormal hemoglobin production. Hemoglobin is the protein in red blood cells that carries oxygen throughout the body. Hemoglobinopathies can cause anemia, fatigue, and other health problems. Treatment for hemoglobinopathies typically involves medications to increase red blood cell production, reduce symptoms, and prevent complications.
The hemoglobinopathies drug market is a subset of the hematological drugs market. It includes drugs used to treat hemoglobinopathies, such as hydroxyurea, decitabine, and l-glutamine. These drugs are used to reduce the severity of symptoms, increase red blood cell production, and prevent complications.
Companies in the hemoglobinopathies drug market include Novartis, Pfizer, GlaxoSmithKline, Merck, and Sanofi. These companies produce and market drugs used to treat hemoglobinopathies. Show Less Read more